Sun Pharmaceutical Industries announced the U. S. launch of the
website for its long-term care (LTC) division, www.sunltc.com.
The new website presents Sun
Pharma s LTC portfolio of alternative formulation products and underscores Sun Pharma s
commitment to meeting the needs of the up to 40% of American adults who cannot or will not
swallow solid medication forms.
Sun Pharma s LTC portfolio includes the first and only U.
S. Food and Drug Administration (FDA)-
approved extended-release sprinkle formulation of metoprolol succinate; the first and only FDA approved sprinkle formulation of delayed-release duloxetine; and the first and only approved
sprinkle formulation of rosuvastatin, Ezallor Sprinkle (rosuvastatin) immediate-release